# JT001 (VV116) for the Treatment of COVID-19

> **NCT05582629** · PHASE3 · COMPLETED · sponsor: **Shanghai Vinnerna Biosciences Co., Ltd.** · enrollment: 1369 (actual)

## Conditions studied

- Mild to Moderate COVID-19

## Interventions

- **DRUG:** JT001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05582629
- **Lead sponsor:** Shanghai Vinnerna Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-21
- **Primary completion:** 2023-02-14
- **Final completion:** 2023-02-14
- **Target enrollment:** 1369 (ACTUAL)
- **Last updated:** 2023-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582629, "JT001 (VV116) for the Treatment of COVID-19". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05582629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*